Paul R, Hofmann R, Schwarzer J U, Stepan R, Feldmann H J, Kneschaurek P, Molls M, Hartung R
Urologische Klinik und Poliklink der TU München, Klinikum rechts der Isar, Munich, Germany.
World J Urol. 1997;15(4):252-6. doi: 10.1007/BF01367663.
We report on a novel protocol involving iridium 192 high-dose-rate brachytherapy and follow-up of up to 130 months in patients with prostatic carcinoma. Using regional anesthesia, five to seven hollow needles are placed within the prostate by perineal puncture under ultrasound guidance. A 9-Gy prostate dose is applied followed by 30 min of hyperthermia (since 1991). This treatment is repeated once after 7 days; 2 weeks later, 18 x 2-Gy external beam radiation (small-field prostate) is added as percutaneous dose saturation. Since 1984 we have treated 40 patients with this protocol. Local tumor control was achieved by means of prostatic biopsy at 18 months after therapy and determination of prostate-specific antigen (PSA) values in about 70% of the patients; after a mean follow-up period of more than 6 years (16-130 months), 80% of the patients show either no evidence of disease or stable disease. We therefore conclude that iridium 192 high-dose-rate brachytherapy is a useful alternative in the treatment of localized prostate cancer in patients who are not eligible for radical prostatectomy.
我们报告了一种新的治疗方案,该方案涉及铱192高剂量率近距离放射治疗,并对前列腺癌患者进行了长达130个月的随访。采用区域麻醉,在超声引导下经会阴穿刺将5至7根空心针置入前列腺内。给予9 Gy的前列腺剂量,随后进行30分钟的热疗(自1991年起)。7天后重复该治疗一次;2周后,增加18次每次2 Gy的外照射(小野前列腺照射)作为经皮剂量饱和。自1984年以来,我们已用该方案治疗了40例患者。通过治疗后18个月时的前列腺活检以及约70%患者的前列腺特异性抗原(PSA)值测定来实现局部肿瘤控制;在平均随访超过6年(16 - 130个月)后,80%的患者显示无疾病证据或疾病稳定。因此,我们得出结论,铱192高剂量率近距离放射治疗对于不适合根治性前列腺切除术的局限性前列腺癌患者是一种有用的替代治疗方法。